Status:
TERMINATED
Interest of the Presepsin Assay as a Biomarker of Bacterial Infection, in the Management of Newborns and Infants Under 3 Months of Age Admitted for Fever in Pediatric Emergency Service (Presepsin)
Lead Sponsor:
University Hospital, Clermont-Ferrand
Collaborating Sponsors:
Mitsubishi Chemical Europe
Conditions:
Newborn Sepsis
Fever
Eligibility:
All Genders
1-3 years
Brief Summary
The purpose of this study is to validate presepsin as a biological marker for identifying bacterial fever among febrile syndromes of infants under three months of age. Clearly, our goal is to determin...
Detailed Description
An exploratory proof of concept that evaluates an innovative and minimally invasive diagnostic technique, with brief, monocentric longitudinal follow-up, this study aims to validate presepsin as a bio...
Eligibility Criteria
Inclusion
- Children under 3 months old with fever, a rectal temperature greater than or equal to 38 ° C, presenting at the pediatric emergency of the Estaing Hospital or directly in pediatric intensive care unit of the Estaing Hospital.
- Coverage by a social security scheme
Exclusion
- Failure to perform a blood test
- Children who received antibiotics before admission.
- Refusal of participation by the legal representatives of the child
- Concomitant participation of the child in a therapeutic trial or other clinical study that may influence the results of this research
Key Trial Info
Start Date :
July 29 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 29 2020
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT04076345
Start Date
July 29 2019
End Date
July 29 2020
Last Update
October 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Clermont-Ferrand
Clermont-Ferrand, Auvergne, France, 63003